Evaluation of Growth Differentiation Factor-5 Levels in Umbilical Cord Blood and Its Association with Neonatal Outcomes and Maternal Diseases
The European Research Journal · 2026-12-01 · 1424-1430
DOI: 10.18621/eurj.1294 ↗Abstract
Objective: To evaluate the association of umbilical cord blood growth differentiation factor-5 (GDF-5) levels with neonatal clinical outcomes and maternal diseases, given its pivotal role in neurodevelopment, tissue differentiation, and repair processes. Methods: This prospective, single-center study enrolled 180 neonates born between 2015 and 2016. Serum GDF-5 concentrations were determined using a commercially available quantitative sandwich enzyme-linked immunosorbent assay (ELISA) kit (SunRed Biotechnology Company) according to the manufacturer's instructions. Neonatal demographic characteristics and maternal complications were analyzed in relation to GDF-5 levels. Results: The neonatal cohort comprised 58.9% (n = 106) males and 41.1% (n = 74) females. GDF-5 levels exhibited no significant differences when evaluated across newborn sex, mode of delivery, birth weight, gestational age, or postnatal pathologies (P > .05). However, neonates born to mothers complicated by placenta previa demonstrated significantly lower GDF-5 concentrations compared to those without placenta previa (P = .02). Conclusions: While umbilical cord blood GDF-5 levels are not correlated with the majority of neonatal outcomes, their significant reduction in cases of placenta previa suggests that GDF-5 may play a role in placental pathology-related processes.
EUVIMED